Abstract: The present invention provides a composition comprising L-carnitine in a suitable vehicle for topical application in an effective amount. The present compositions are useful in improving or healing skin conditions including wrinkling, dry or peeling skin, and burns (particularly sunburn), and in healing and prevention of scar formation, particlarly that caused by infection by a pathogen. Treatment methods are also provided.

Abstract: Compositions for the transdermal delivery of azatadine and the use of such compositions in the treatment of allergic reactions are disclosed.

Abstract: Anhydrous vehicles for topical use, e.g. for use with topically active pharmaceutical agents, including antibiotics, anti-fungal agents, anti-inflammatory agents, antihistamines, antipruritics and local anesthetics, comprise principally from about 60 to about 90% by weight of at least one glycol solvent and from about 2 to about 20% by weight etherified saturated fatty alcohol having a total chain length of from 20 to 216 carbon atoms. The vehicles are substantially free of water, greasy substances and fatty alcohols having less than 16 carbon atoms. The vehicles have a cream-like consistency and can also incorporate suitable compatible plasticizers, coupling agents, penetrants and the like.

Abstract: There is disclosed a process for treating gram negative septicemia/endotoxemia to decrease lung damage in a host by parenterally administering a therapeutically effective amount of antithrombin III and alpha-1-proteinase inhibitor.

Abstract: Cosmetic Base composition exhibiting therapeutic properties includes an acyl fatty acid lactylate ester or alkali metal salt thereof, a sucrose fatty acid ester, and a solvent.

Abstract: The invention provides an ointment composition for treating skin irritations such as diaper rash and decubitus. The composition includes zinc oxide, boric acid, karaya gum, peruvian balsam, cod liver oil and an appropriate solvent and pharmaceutical carrier.

Abstract: Processes for use of interleukin-1 as an anti-arthritic agent are disclosed, comprising administration of an effective quantity of interleukin-1 (IL-1) in association with a pharmaceutical carrier, to an animal, including man.

Abstract: The compounds and pharmaceutical compositions of Formula A, wherein Z is hydrogen or --C(O)R, where R is lower alkyl or aryl, and the pharmaceutically acceptable salts thereof, are useful as immunosuppressive agents, anti-inflammatory agents, anti-tumor agents, anti-viral agents, and anti-psoriatic agents.

Abstract: Inflammation, acute and/or chronic, is treated with a CIF (TGF-.beta.). The CIF may be administered locally or symstemically, depending upon the indication, and does not require coadministraion of activator or cofactor for efficacy.

Abstract: Pharmaceutical compositions which are suitable for topical application in the treatment of bacterial and/or fungal infections are described. The compositions comprise a synergistic mixture of a silver compound and an azole derivative together with a pharmaceutically acceptable carrier therefor. The compositions may be applied topically in the treatment of burns ulcers and other skin lesions, general skin infections and also in the treatment of infections of the mucous membranes. Preferred compositions contain silver sulphadiazine and clotrimazole or metronidazole. The compositions may be applied as ointments, gels, pessaries, tablets and the like.

Abstract: A controlled release treatment composition and method of use are disclosed. The composition includes a bioadhesive and an effective amount of a treating agent. The bioadhesive is a water-swellable, but water-insoluble, fibrous, cross-linked carboxy-functional polymer containing (a) a plurality of repeating units of which at least about 80 percent contain at least one carboxyl functionality, and (b) about 0.05 to about 1.5 percent cross-linking agent substantially free from polyalkenyl polyether.

Abstract: Analogs of the marine natural product manoalide are useful in treating mammals, including humans, in need of a drug having analgesic/anti-inflammatory, immunosuppressive, and/or antiproliferative activity.

Abstract: There is disclosed a method for the treatment of immunoinflammatory conditions, such as allergy, anaphylaxis, asthma and inflammation in mammals which comprises administering to a mammal so afflicted an effective amount of a compound having the formula: ##STR1## wherein R.sup.1 and R.sup.2 are each, independently, hydrogen, hydroxy, lower alkyl, lower alkoxy, haloloweralkyl, haloloweralkyl sulfony., halo or nitro;R.sup.3 is hydrogen, lower alkyl, or aryl of 7-12 carbon atoms;X is ##STR2## A is --CH.sub.2 --,--O-- or --S--; m is 0-8;n is 0-7, with the proviso that m+n.ltoreq.

Abstract: Biphenylylpropionic acid derivatives of the formula: ##STR1## wherein R is an alkylcarbonyloxyalkyl group or an alkenylcarbonyloxyalkyl group having the formula: ##STR2## wherein R.sup.1 is a lower alkyl group having 1 to 5 carbon atoms and R.sup.2 is an alkyl group having 1 to 15 carbon atoms or an alkenyl group having 2 to 8 carbon atoms, or a lactone having the formula: ##STR3## wherein R.sup.3 and R.sup.4 are hydrogen atom or a lower alkyl group having 1 to 2 carbon atoms, and n is an integer of 1 or 2. The compounds have excellent anti-inflammatory, analgesic and antipyretic activities. Moreover, the compounds have no irritation, rapid and long-acting, and high safety margin.

Abstract: The invention includes novel pharmaceutical compositions for topical use in the therapy or prophylaxis of inflammatory skin diseases, a method of treating one or more such diseases, a novel, optically active N-substituted-isobutyramide as an active ingredient and a process for the manufacture of said novel active ingredient.

Abstract: A method of enhancing the wound-healing process in animals utilizing glycyl-1-histidyl-1-lysine: copper(II) (GHL-Cu) is disclosed. GHL-Cu functions as a superoxide dismutase which detoxifies tissue-damaging oxygen radicals, but does not evoke an antigenic response. A method of treating inflammatory conditions in animals and a method of reducing the traumatic effects in animals occurring subsequent to major tissue damage utilizing GHL-Cu is also disclosed.

Abstract: Disclosed herein are dialkanoyloxybenzylidene dialkanoate represented by the formula, ##STR1## wherein X.sup.1 and X.sup.2 represent respectively alkanoyloxy group and a pharmaceutical composition in dosage unit form which comprises a dosage effective for the treatment of inflammatory disease of the dialkanoyloxybenzylidene dialkanoate as an active ingredient thereof.

Abstract: Novel compounds and compositions which inhibit SRS-A in mammals are disclosed. Methods for preparing said compounds and compositions and methods for their use for treating allergic reactions, inflammation and for reducing the severity of myocardial infarction resulting from heart attack are disclosed.Useful intermediates for preparing said compounds are also disclosed.

Abstract: The invention relates to topical antiinflammatory medicament formulations which also have analgesic activity and contain 2-(2-hydroxyethoxy)-ethyl N-(.alpha.,.alpha.,.alpha.,-trifluoro-m-tolyl) anthranilate as the active ingredient and an adjuvant which is preferably a triglyceride.

Abstract: A method for treating a patient suffering from muscular or joint diseases caused by inflammation comprising the steps of administering to the patient a therapeutically effective amount of a composition comprising 2,4,6-triiodophenol or the pharmacologically acceptable salts thereof, in combination with a pharmaceutically acceptable carrier.

Abstract: Substituted 1-oxa-dethiacephalosporins are found to be effective elastase inhibitors and thereby useful anti-inflammatory/antidegenerative agents.

Abstract: Disclosed are aqueous, stable, relatively concentrated solutions of diclofenac, which contain a mixture of propylene glycol and polyethylene glycol in defined quantitative proportions. The solutions preferably contain a local anesthetic such as lidocaine and a reducing agent as stabilizer.

Abstract: The present invention is a cosmetic composition that raffinose ester of higher fatty acid having carbon atoms from 14 to 20 and cane sugar fatty acid ester are used in parallel, further solcoseryl is compounded to the above. The composition according to the present invention are stable and do not give the irritation on the skin, has no variable nature and has an excellent moisture retaining ability, and then can give the cosmetics which the feeling obtained by employing said cosmetics is very satisfactory. Further the solcoseryl that the substance which deoxyribonucleic acid is dissolved in the raffinose ester of higher fatty acid is added under the sterile condition can be compounded in this cosmetic composition.

Abstract: This invention relates to new xylane sulfates having an apparent molar weight comprised between 7000 and 12000.This invention relates also to a process for their preparation by fractionation, and to the therapeutic application thereof as anti-thrombosis and hypolipemic agents.

Abstract: Improved cosmetic compositions for skin care containing an amount sufficient for skin care of glycoprotein extracts of lysed microbial bodies of Hafnia species or strains prepared by (a) cultivating a microbial Hafnia strain until complete development of microbial bodies, (b) subjecting the microbial bodies to lysis, (c) treating the lysate with at least one solvent for delipidation and depigmentation of the lysate, (d) dissolving the resulting product, (e) subjecting the solution to centrifugation and (f) optionally subjecting the resulting product to ultrafiltration and a method of improving a person's skin.

Abstract: The compounds of the present invention comprise substituted 1,5-diphenyl-2-pyrrolepropionic acids and derivatives thereof represented by the formula: ##STR1## wherein: R represents hydroxy, alkoxy of from 1 to 6 carbon atoms, inclusive, or amino; R.sup.1 represents hydrogen or acyl of from 2 to 7 carbon atoms, inclusive; and X represents hydrogen, halogen, hydroxy or alkoxy of from 1 to 6 carbon atoms, inclusive. The compounds of the present invention are 5-lipoxygenase inhibitors and, therefore, are useful in the treatment of local and systemic inflammation, allergy and hypersensitivity reactions and other disorders in which agents formed in the 5-lipoxygenase metabolic pathway are involved.

Abstract: Pharmaceutical compositions comprising mixtures of xanthan gum and locust bean gum in a specified range of ratios have been found to exhibit synergistic effects in an in vitro test model. Pharmaceutical compositions adapted for oral administration comprising mixtures of xanthan gum and locust bean gum in the range of ratios are described for use in the treatment of diabetes or of satiety.

Abstract: A new and improved vehicle for delivering pharmaceutical ingredients to the human skin in a manner whereby the bioavailability, subcutaneous adsorption, and effectiveness of the active ingredient are remarkably enhanced. The vehicle comprises a volatile silicone, a fatty alcohol having from 12-22 carbon atoms, a preselected active ingredient; and such preservatives or emulsifying agents as may be warranted.

Abstract: Compounds having the formula: ##STR1## are antagonists of leukotrienes of C.sub.4, D.sub.4 E.sub.4 and the slow reacting substance of anaphylaxis.As such, these compounds will be useful as anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.

Abstract: Compounds selected from the group consisting of 4H-1,2,4-triazoles of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 may be in different positions of the benzene ring, R.sub.1, R.sub.3 and R.sub.4 are individually selected from the group consisting of hydrogen, --OH, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, halogen, --CF.sub.3, --NO.sub.2, --NH.sub.2 and NH--AlK and ##STR2## R.sub.2 is selected from the group consisting of hydrogen, --OH, alkyl of 1 to 4 carbon atoms, halogen, --CF.sub.3, --NO.sub.2, --NH.sub.2, --NH--AlK and ##STR3## and AlK, AlK.sub.1 and AlK.sub.2 are alkyl of 1 to 4 carbon atoms or R.sub.1 and R.sub.2 together and/or R.sub.3 and R.sub.4 together are methylenedioxy, R is selected from the group consisting of ethyl, --CH.sub.2 --COOH and CH.sub.2 --COOAlK.sub.3 and AlK.sub.3 is alkyl of 1 to 4 carbon atoms and their non-toxic, pharmaceutically acceptable acid addition salts, with the proviso that R.sub.1, R.sub.2, R.sub.3 and R.sub.

Abstract: There is provided a dermatological composition for treating acne and similar skin lesions which comprises benzoyl peroxide and gel from the plant Aloe vera. The gel from Aloe vera helps to reduce specific undesirable reactions which would otherwise result from the use of benzoyl peroxide to treat skin lesions.

Abstract: A method of treating various sensitive animal body tissues comprising applying to the tissue a solution prepared from specially processed seawater. The solution is prepared by filtering off-shore seawater to remove debris in small organisms, sterilizing the filtered solution and diluting thereafter with tap water or distilled water to lower the solution's osmolality to about 280 mOs, which renders the solution compatible and isotonic with the tissue to be treated.

Abstract: A novel compound bis-(N,N-dimethyl-N-carbodecyloxymethyl-N-ethyleneammonium)-sulphide dichloride of the formula ##STR1## A method for preparing said novel compound comprising quaternization of bis-(.beta.-dimethylaminoethyl)-sulphide with monochloroacetic acid decyl ester, molar ratio of said reagents being not more than 1:2.A chemotherapeutic antimicrobial preparation comprising said novel compound as an active principle in combination with a pharmaceutical carrier.A plant growth regulator in the form of an aqueous solution of said novel compound in a concentration of from 0.0001 to 0.1 wt. %.

Abstract: There is disclosed a polyprenylcarboxylic acid amide of the formula: ##STR1## wherein R.sup.1 represents a hydrogen atom or a lower alkyl group, R.sup.2 represents a hydrogen atom or a group of the formula: --COOR.sup.4 in which R.sup.4 represents a lower alkyl group, R.sup.3 represents a hydrogen atom or an OH group and n represents an integer of 1 to 6.

Abstract: The present disclosure relates to the use of thromboxane synthase inhibitors as antiobesity agents and insulin lowering agents. Such compounds fall into a variety of classes among which are 1-substituted imidazoles, 4-substituted imidazoles, 3-substituted pyridines, 3-substituted indoles, 4-substituted pyrimidines, 5-substituted tetrazoles, pyrazolidines, quinazolines, and substituted xanthene carboxylic acids.